Free exam prep

C-NPT Neonatal Pediatric Transport

6.1 Vasoactive Infusions & Inotropes (Epinephrine, Dopamine, Dobutamine, Milrinone)

Q: A transport team is dispatched to a community hospital for a 36-week gestation neonate presenting at 18 hours of life with lethargy, poor perfusion, metabolic acidosis, and profound cardiogenic shock refractory to fluid administration. The referring hospital physician initiated a dopamine infusion at 15 mcg/kg/min, but the neonate's mean arterial pressure continues to decline and peripheral extremities are mottled. Based on developmental receptor pharmacology, what explains this clinical failure and what is the most appropriate corrective pharmacological intervention?

The neonatal myocardium possesses immature sarcoplasmic reticulum and depleted sympathetic nerve terminals with inadequate endogenous norepinephrine; discontinue dopamine and initiate an epinephrine infusion at 0.05 to 0.1 mcg/kg/min.. Neonates, especially premature infants, exhibit structural and functional immaturity of the myocardium, including disorganized myofibrils, decreased sarcoplasmic reticulum calcium storage, and poorly developed sympathetic nerve innervation with depleted endogenous norepinephrine stores. Because dopamine relies heavily on releasing stored norepinephrine from sympathetic nerve terminals, it acts as a weak indirect agonist in neonates and at high doses (>10 mcg/kg/min) primarily stimulates peripheral alpha-1 receptors, markedly increasing afterload on a non-compliant ventricle. Epinephrine acts directly on myocardial beta-1 and vascular adrenergic receptors without requiring endogenous neurotransmitter stores, which is why it is often preferred when neonatal shock is driven by poor myocardial function. Because this infant is 18 hours old and in cardiogenic shock, a ductal-dependent systemic lesion should also be considered, with PGE1 started if one is suspected (Section 8.2).

Q: A 3-year-old child with repaired congenital heart disease is being transferred for acute low cardiac output syndrome, elevated pulmonary vascular resistance (PVR), and severe biventricular dysfunction. The transport team decides to initiate a continuous milrinone infusion. Which pharmacological mechanism of action and operational transport administration rule must the transport clinician apply?

Milrinone inhibits phosphodiesterase enzyme type 3 (PDE-3), increasing intracellular cAMP to produce inotropy and systemic/pulmonary vasodilation; loading boluses should be omitted in transport to prevent severe hypotension.. Milrinone is a non-adrenergic bipyridine derivative that selectively inhibits phosphodiesterase type 3 (PDE-3), preventing the degradation of cyclic adenosine monophosphate (cAMP) in cardiac myocytes and vascular smooth muscle. This produces positive inotropy, enhanced lusitropy (diastolic relaxation), and reduces both systemic vascular resistance (SVR) and pulmonary vascular resistance (PVR)—an 'inodilator' effect. In the transport environment, the standard hospital loading bolus (50 mcg/kg) must be omitted or avoided because rapid administration triggers sudden, profound peripheral vasodilation and catastrophic hypotension. Instead, a continuous maintenance infusion (0.25 to 0.75 mcg/kg/min) is initiated.

Q: During ground transport of a 6-year-old child in septic shock receiving a peripheral norepinephrine infusion at 0.4 mcg/kg/min, the transport nurse notices that the IV site on the right forearm is swollen, firm, blanched, and cool to the touch. The monitor shows no change in heart rate, but the infusion pump is alarming high pressure. What is the immediate pharmacological antidote and clinical management sequence?

Stop the infusion immediately, attempt gentle aspiration of residual drug from the catheter, remove the line, and infiltrate phentolamine (0.1 to 0.2 mg/kg diluted in normal saline) subcutaneously into the ischemic zone.. Peripheral extravasation of potent alpha-1 adrenergic agonists such as norepinephrine, epinephrine, or high-dose dopamine causes severe, localized microvascular spasm and severe dermal ischemia that can rapidly progress to full-thickness skin necrosis and gangrene. The correct management sequence is: stop the infusion immediately, gently aspirate residual drug from the catheter hub before removal, remove the cannula, and administer phentolamine (Regitine). Phentolamine is a competitive alpha-adrenergic antagonist given at 0.1 to 0.2 mg/kg (up to 5 to 10 mg) diluted in normal saline, infiltrated circumferentially with a fine-gauge needle into the blanched, ischemic tissue to restore microvascular blood flow.

Key Takeaways

Vasoactive selection depends strictly on hemodynamic receptor affinity: alpha-1 stimulation drives systemic vasoconstriction and afterload elevation, beta-1 increases myocardial contractility and heart rate, beta-2 promotes smooth muscle vasodilation, and phosphodiesterase-3 inhibition delivers inotropic support with afterload reduction.
Neonatal myocardium has immature sarcoplasmic reticulum, disorganized myofibrils, and immature sympathetic innervation, so dopamine's indirect (norepinephrine-releasing) inotropic effect may be blunted; direct-acting epinephrine is often preferred when myocardial dysfunction predominates.
Epinephrine is commonly chosen for pediatric cold septic shock (0.05-0.1 mcg/kg/min for beta-1 inotropy; >0.1-1.0 mcg/kg/min for alpha-1 vasoconstriction), while norepinephrine (0.05-1.0 mcg/kg/min) is commonly chosen for warm vasodilatory shock; the Surviving Sepsis Campaign recommends epinephrine or norepinephrine over dopamine without naming one first-line agent.
Milrinone (0.25-0.75 mcg/kg/min) is a non-adrenergic inodilator that decreases both systemic and pulmonary vascular resistance without increasing myocardial oxygen consumption, making it ideal for PPHN and cardiac dysfunction, but transport crews must avoid loading boluses to prevent profound hypotension.
Peripheral extravasation of alpha-adrenergic vasopressors causes severe local ischemic necrosis; immediate antidote treatment requires multiple subcutaneous infiltrations of phentolamine (0.1-0.2 mg/kg up to 5-10 mg diluted in normal saline) into the blanched tissue.

Last updated: September 2026

Vasoactive Infusions & Inotropes (Epinephrine, Dopamine, Dobutamine, Milrinone)

Critical care interfacility transport demands rapid identification and precise hemodynamic stabilization of decompensating circulatory shock. Whether managing a preterm neonate with cardiogenic collapse from closing ductal architecture or an adolescent with hyperdynamic septic shock, transport clinicians must select, calculate, and titrate vasoactive infusions based on complex receptor physiology, developmental pharmacology, and vehicle dynamics.

Adrenergic & Intracellular Receptor Pharmacology

Vasoactive infusions exert their physiological effects through specific adrenergic and intracellular signaling cascades. Mastery of receptor affinities is fundamental to tailoring hemodynamic support to patient-specific pathophysiology:

Alpha-1 ( $\alpha_1$ ) Receptors: Located primarily on vascular smooth muscle. Stimulation activates the phospholipase C pathway, increasing intracellular inositol trisphosphate ( $\text{IP}_3$ ) and calcium, producing arterial and venous vasoconstriction. This elevates systemic vascular resistance (SVR), raises mean arterial pressure (MAP), and increases ventricular afterload.
Alpha-2 ( $\alpha_2$ ) Receptors: Predominantly presynaptic autoreceptors in the central and peripheral nervous systems that inhibit endogenous norepinephrine release, attenuating sympathetic outflow.
Beta-1 ( $\beta_1$ ) Receptors: Located in cardiac myocytes, the sinoatrial (SA) node, and atrioventricular (AV) node. Activation stimulates adenylyl cyclase, converting adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), augmenting protein kinase A (PKA). This enhances intracellular calcium influx during systole, delivering potent positive inotropy (contractility), chronotropy (heart rate), dromotropy (conduction velocity), and lusitropy (myocardial relaxation).
Beta-2 ( $\beta_2$ ) Receptors: Located on bronchial and vascular smooth muscle (especially skeletal and splanchnic beds). Activation increases cAMP, promoting smooth muscle relaxation that results in systemic vasodilation (decreased SVR) and bronchodilation.
Dopaminergic ( $\text{DA}_1$ and $\text{DA}_2$ ) Receptors: Located in renal, mesenteric, coronary, and cerebral arterial beds. Low-affinity stimulation activates adenylyl cyclase, causing localized vasodilation.
Phosphodiesterase-3 (PDE-3) Inhibition: Intracellular enzyme inhibition preventing cAMP breakdown in cardiac myocytes and vascular smooth muscle, enhancing contractility while driving systemic and pulmonary vasodilation.

Comparative Pharmacodynamics of Transport Vasoactive Infusions

Medication	Receptor Affinity Profile	Typical Infusion Range	Primary Clinical Indications	Hemodynamic & Transport Considerations
Epinephrine	$\beta_1 > \beta_2 > \alpha_1$ (dose-dependent)	0.05 – 1.0 mcg/kg/min	Cold septic shock, post-cardiac arrest myocardial dysfunction, anaphylaxis	Low dose (0.05–0.1 mcg/kg/min) boosts inotropy; high dose (>0.1–1.0 mcg/kg/min) produces severe $\alpha_1$ vasoconstriction and tachycardia. Induces transient hyperlactatemia via $\beta_2$ -mediated hepatic glycolysis.
Norepinephrine	$\alpha_1 > \beta_1 \gg \beta_2$	0.05 – 1.0 mcg/kg/min	Warm (vasodilatory) septic shock, neurogenic shock, post-bypass vasoplegia	Potent systemic vasoconstrictor with modest $\beta_1$ inotropy; restores diastolic blood pressure and coronary perfusion pressure without excessive tachycardia.
Dopamine	$\text{DA}_1$ (low) $\rightarrow \beta_1$ (mid) $\rightarrow \alpha_1$ (high)	2 – 20 mcg/kg/min	Second-line pediatric shock, symptomatic bradycardia	1–3 mcg/kg/min: renal/mesenteric vasodilation (unproven benefit); 5–10 mcg/kg/min: $\beta_1$ inotropy; 10–20 mcg/kg/min: $\alpha_1$ vasoconstriction. Raises blood pressure in many preterm infants, mainly through vasoconstriction.
Dobutamine	$\beta_1 > \beta_2 > \alpha_1$	2 – 20 mcg/kg/min	Cardiogenic shock, low cardiac output post-cardiac surgery	Pure synthetic inotrope with mild peripheral $\beta_2$ vasodilation; reduces afterload while increasing cardiac index. May cause tachycardia and precipitate ventricular arrhythmias.
Milrinone	Selective PDE-3 Inhibitor (Non-adrenergic)	0.25 – 0.75 mcg/kg/min	PPHN, post-operative congenital heart disease, severe left/right ventricular failure	Inodilator: augments contractility, improves diastolic relaxation (lusitropy), reduces SVR and PVR without increasing myocardial $\text{MVO}_2$ . Bolus must be omitted in transport.

The Neonatal Myocardium & Developmental Limitations of Dopamine

A critical concept on the C-NPT exam is the developmental immaturity of the neonatal and preterm myocardium. Unlike mature pediatric or adult hearts, the neonatal heart operates under distinct structural and physiological constraints:

Myofibrillar Disorganization: Neonatal myocytes contain fewer contractile elements (approximately 30% myofibrils compared to 60% in adults) surrounded by non-contractile mass and collagen. As a result, the neonatal ventricle is stiff, non-compliant, and operates near the peak of its Frank-Starling curve. Stroke volume cannot increase substantially; cardiac output is strictly rate-dependent.
Calcium Handling Immaturity: The sarcoplasmic reticulum (SR) and transverse tubules (T-tubules) are poorly developed. Neonatal myocytes cannot mobilize large intracellular calcium stores and depend almost exclusively on extracellular calcium influx across the sarcolemma. Hypocalcemia rapidly halts neonatal myocardial contractility.
Depleted Sympathetic Innervation: Autonomic sympathetic nerve terminals within the neonatal myocardium are structurally immature and deficient in endogenous norepinephrine stores. Conversely, myocardial adrenergic receptors are fully present and functional.

Why Dopamine May Fail in Neonatal Myocardial Dysfunction

Dopamine exerts its positive inotropic effect through a dual mechanism: direct stimulation of myocardial $\beta_1$ receptors and indirect release of endogenous norepinephrine from sympathetic nerve terminals. Because preterm and term neonates have depleted norepinephrine stores and impaired uptake-storage mechanisms, dopamine acts as a very weak indirect agonist. High doses of dopamine (>10 mcg/kg/min) in neonates stimulate peripheral vascular $\alpha_1$ receptors, raising afterload against an already non-compliant, failing ventricle, which can further reduce cardiac output.

In contrast, epinephrine is a direct-acting catecholamine that binds directly to functional $\beta_1$ and $\alpha_1$ receptors without requiring endogenous neurotransmitter stores. For pediatric septic shock, the 2020 Surviving Sepsis Campaign guidelines suggest epinephrine or norepinephrine rather than dopamine. In neonates, dopamine remains widely used for hypotension and raises blood pressure in many preterm infants, but epinephrine is often preferred when poor myocardial function predominates.

Epinephrine & Norepinephrine in Pediatric Resuscitation & Septic Shock

Septic shock in pediatric patients classically presents along two hemodynamic phenotypes that guide vasoactive selection. The 2020 Surviving Sepsis Campaign pediatric guidelines suggest epinephrine or norepinephrine rather than dopamine and found too little evidence to recommend one over the other, so clinicians choose by physiology:

1. Cold Shock (Low Cardiac Output, High SVR)

Characterized by prolonged capillary refill (>2–3 seconds), mottled cool extremities, weak thready central pulses, narrow pulse pressure, and oliguria. The myocardium is stunned, while compensatory neuroendocrine vasoconstriction elevates SVR.

Usual Agent: Epinephrine (0.05–0.1 mcg/kg/min initially, titrated up to 0.3–0.5 mcg/kg/min).
Mechanism: Low-to-moderate doses activate $\beta_1$ receptors to augment stroke volume and cardiac index, while $\beta_2$ activity balances intense $\alpha_1$ vasoconstriction, improving systemic perfusion.
Exam Warning on Lactate: Epinephrine stimulates hepatic $\beta_2$ receptors, accelerating glycogenolysis and aerobic glycolysis. This routinely generates a benign transient elevation in plasma lactate despite improving organ perfusion. Clinicians must evaluate clinical markers (capillary refill, urine output, central venous oxygen saturation $\text{ScvO}_2 > 70\%$ ) rather than treating the lactate number in isolation.

2. Warm Shock (High Cardiac Output, Low SVR)

Characterized by flash capillary refill (<1 second), bounding peripheral pulses, wide pulse pressure, warm extremities, and profound systemic hypotension resulting from cytokine-mediated nitric oxide release and vascular smooth muscle vasoplegia.

Usual Agent: Norepinephrine (0.05–0.1 mcg/kg/min, titrated to 0.5–1.0 mcg/kg/min).
Mechanism: Potent $\alpha_1$ receptor agonism produces intense arterial and venous constriction, restoring SVR, diastolic perfusion pressure, and mean arterial pressure without provoking excessive tachycardia.

Dobutamine & Milrinone: Inotropic Support & Afterload Reduction

When ventricular failure is characterized by severe systolic dysfunction and elevated ventricular afterload (e.g., dilated cardiomyopathy, acute myocarditis, or post-cardiopulmonary bypass), standard vasopressors that raise afterload worsen myocardial work.

Dobutamine (2–20 mcg/kg/min)

A synthetic catecholamine that binds $\beta_1$ and $\beta_2$ receptors in a 3:1 ratio. It increases myocardial contractility while inducing mild peripheral vasodilation. Dobutamine is particularly effective in pediatric cardiogenic shock when blood pressure is preserved, as it increases cardiac index while reducing ventricular wall stress.

Milrinone (0.25–0.75 mcg/kg/min)

Milrinone is a non-adrenergic bipyridine that selectively inhibits phosphodiesterase enzyme type 3 (PDE-3). By blocking the breakdown of cAMP in cardiac myocytes, milrinone increases intracellular calcium during systole (inotropy) and accelerates calcium reuptake into the SR during diastole, markedly improving myocardial relaxation (lusitropy). In systemic and pulmonary vascular smooth muscle, elevated cAMP causes calcium extrusion, producing potent systemic and pulmonary arterial vasodilation (decreasing both SVR and PVR).

Transport Indications: Persistent pulmonary hypertension of the neonate (PPHN), left-to-right shunts with elevated PVR, post-operative cardiac surgical patients, and severe left ventricular failure.
Transport Warning Regarding Loading Bolus: In hospital ICU protocols, a loading dose of 50 mcg/kg is often administered over 10–60 minutes. In critical care transport, the loading bolus is strictly contraindicated or strongly avoided. Rapid bolus administration triggers sudden, unheralded peripheral vasodilation and catastrophic hypotension. Transport clinicians initiate a continuous maintenance infusion at 0.25–0.375 mcg/kg/min and titrate upward slowly without a bolus. Milrinone has an elimination half-life of 2–4 hours (longer in renal insufficiency), necessitating patience during steady-state titration.

Smart Pump Safety, Compatibility & Extravasation Protocols

Transporting unstable infants receiving high-potency vasoactive infusions poses significant mechanical and pharmacological hazards:

Smart Infusion Pump Management

Always utilize dedicated syringe pumps equipped with dose-error reduction systems (DERS) and soft/hard limits programmed specifically for neonatal and pediatric parameters.
Dead Space & Manifold Dynamics: Vasoactive infusions must be connected to the most proximal port of the vascular access device to eliminate carrier fluid dead volume. Unintentional boluses occur when high-flow maintenance fluids flush a manifold containing residual concentrated catecholamines. Conversely, carrier fluids running at very low rates (<1 mL/hr) delay medication arrival to the systemic circulation by tens of minutes.
Ensure dedicated, non-interrupted lines for vasoactive infusions; never administer push medications, blood products, or sodium bicarbonate through an active inotrope line.

Peripheral Extravasation & Phentolamine Management

While central venous access (umbilical venous catheter, PICC, internal jugular) is preferred, transport teams frequently manage patients with peripheral IV lines. Extravasation of alpha-adrenergic agonists (norepinephrine, epinephrine, high-dose dopamine) produces severe local vasoconstriction, tissue ischemia, and full-thickness dermal necrosis.

Clinical Protocol: Extravasation Antidote

If peripheral extravasation occurs:

Stop the infusion immediately; do not remove the vascular catheter initially.

Gently aspirate as much extravasated drug from the catheter hub as possible, then remove the catheter.

Administer Phentolamine (Regitine), a competitive alpha-adrenergic antagonist: dose 0.1 to 0.2 mg/kg (maximum 5 to 10 mg), reconstituted in 5–10 mL of preservative-free normal saline.

Using a small-gauge (25- to 27-gauge) needle, infiltrate the phentolamine solution subcutaneously in a circumferential pattern directly into the blanched, ischemic tissue. Hyperemia and tissue reperfusion should occur within minutes.

Loading diagram...

Transport Vasoactive Selection Decision Tree

Test Your Knowledge

A transport team is dispatched to a community hospital for a 36-week gestation neonate presenting at 18 hours of life with lethargy, poor perfusion, metabolic acidosis, and profound cardiogenic shock refractory to fluid administration. The referring hospital physician initiated a dopamine infusion at 15 mcg/kg/min, but the neonate's mean arterial pressure continues to decline and peripheral extremities are mottled. Based on developmental receptor pharmacology, what explains this clinical failure and what is the most appropriate corrective pharmacological intervention?

The neonatal myocardium possesses immature sarcoplasmic reticulum and depleted sympathetic nerve terminals with inadequate endogenous norepinephrine; discontinue dopamine and initiate an epinephrine infusion at 0.05 to 0.1 mcg/kg/min.

Dopamine requires active renal clearance to generate inotropic metabolites; increase the dopamine infusion rate to 25 mcg/kg/min to overcome down-regulated renal vascular receptors.

The neonate is experiencing profound alpha-adrenergic receptor desensitization; administer a rapid intravenous loading bolus of milrinone at 50 mcg/kg over 5 minutes.

The patient has primary dopaminergic receptor blockade from maternal medications; substitute dopamine with high-dose phenylephrine at 2 mcg/kg/min to restore afterload.

Test Your Knowledge

A 3-year-old child with repaired congenital heart disease is being transferred for acute low cardiac output syndrome, elevated pulmonary vascular resistance (PVR), and severe biventricular dysfunction. The transport team decides to initiate a continuous milrinone infusion. Which pharmacological mechanism of action and operational transport administration rule must the transport clinician apply?

Milrinone stimulates myocardial beta-1 receptors to promote intracellular calcium influx; a rapid loading bolus of 50 mcg/kg over 2 minutes is required to achieve therapeutic steady state.

Milrinone inhibits phosphodiesterase enzyme type 3 (PDE-3), increasing intracellular cAMP to produce inotropy and systemic/pulmonary vasodilation; loading boluses should be omitted in transport to prevent severe hypotension.

Milrinone acts as a selective alpha-2 presynaptic agonist that decreases central sympathetic outflow; it should only be administered through an umbilical artery catheter to avoid portal vein thrombosis.

Milrinone binds to endothelin-A receptors in pulmonary vascular smooth muscle; it must be co-infused with high-dose calcium gluconate to prevent drug-induced hyperkalemic arrhythmias.

Test Your Knowledge

During ground transport of a 6-year-old child in septic shock receiving a peripheral norepinephrine infusion at 0.4 mcg/kg/min, the transport nurse notices that the IV site on the right forearm is swollen, firm, blanched, and cool to the touch. The monitor shows no change in heart rate, but the infusion pump is alarming high pressure. What is the immediate pharmacological antidote and clinical management sequence?

Immediately apply an ice pack to the site to promote local vasoconstriction, remove the IV catheter, and administer intravenous diphenhydramine 1 mg/kg.

Elevate the extremity, apply topical nitroglycerin paste to the blanched area, and flush the peripheral IV catheter with 10 mL of heparinized saline under high pressure.

Stop the infusion immediately, attempt gentle aspiration of residual drug from the catheter, remove the line, and infiltrate phentolamine (0.1 to 0.2 mg/kg diluted in normal saline) subcutaneously into the ischemic zone.

Double the norepinephrine rate to overcome vascular resistance, leave the peripheral catheter in place, and administer intravenous protamine sulfate at 1 mg/kg.

Sections you finish are checked off in the contents.

Up Next

6.2 Sedation, Analgesia & Neuromuscular Blockade in Transport

Continue learning